![Wills Hughes-Wilson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Wills Hughes-Wilson
Corporate Officer/Principal at
MEREO BIOPHARMA GROUP PLC
Net worth: 17 363 $ as of 31/05/2026
Profile
Alexandra Hughes-Wilson is Chief Patient Access & Commercial Planning at Mereo BioPharma Group Plc since 2018.
Former roles include Chief Patient Access Officer & Senior VP at Swedish Orphan Biovitrum AB from 2016 to 2018, Executive Director at European Biopharmaceutical Enterprises, Vice President-Health & Market Access Policy at Genzyme Corp., and VP-Health & Market Access Policy EMEA at Genzyme Therapeutics Ltd. Education includes a graduate degree from the University of Durham.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 01/02/2026 | 252,375 ( 0.03% ) | 17 363 $ | 31/05/2026 |
Wills Hughes-Wilson active positions
| Companies | Position | Start |
|---|---|---|
| MEREO BIOPHARMA GROUP PLC | Corporate Officer/Principal | 01/03/2018 |
Former positions of Wills Hughes-Wilson
| Companies | Position | End |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Public Communications Contact | 01/01/2018 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Corporate Officer/Principal | - |
European Biopharmaceutical Enterprises
 European Biopharmaceutical Enterprises BiotechnologyHealth Technology Develops biological products | Director/Board Member | - |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | - |
Training of Wills Hughes-Wilson
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
35
1st degree connections
6
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
University of Durham
 University of Durham Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
European Biopharmaceutical Enterprises
European Biopharmaceutical Enterprises BiotechnologyHealth Technology Develops biological products | Health Technology |
Swedish Orphan Biovitrum AB
 Swedish Orphan Biovitrum AB Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceuticals and orphan drugs in the areas of hematology, immunology and specialty care | Health Technology |
Mereo BioPharma Group Plc
 Mereo BioPharma Group Plc BiotechnologyHealth Technology Operates as a biopharmaceutical company | Health Technology |
- Stock Market
- Insiders
- Wills Hughes-Wilson
